{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T21:09:04Z","timestamp":1792012144938,"version":"4.4.0"},"reference-count":151,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100004391","name":"China Medical University Hospital","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004391","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Antimicrobial Agents"],"published-print":{"date-parts":[[2023,5]]},"DOI":"10.1016\/j.ijantimicag.2023.106763","type":"journal-article","created":{"date-parts":[[2023,2,17]],"date-time":"2023-02-17T20:30:42Z","timestamp":1676665842000},"page":"106763","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":33,"title":["Off-label use versus formal recommendations of conventional and novel antibiotics for the treatment of infections caused by multidrug-resistant bacteria"],"prefix":"10.1016","volume":"61","author":[{"given":"Shio-Shin","family":"Jean","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I-Min","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Po-Chuen","family":"Hsieh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dai-Huang","family":"Kuo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi-Lien","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Po-Ren","family":"Hsueh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijantimicag.2023.106763_bib0001","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1016\/j.jmii.2021.07.008","article-title":"Investigation of a cluster of Bacillus cereus bacteremia in neonatal care units","volume":"55","author":"Tsai","year":"2022","journal-title":"J Microbiol Immunol Infect"},{"key":"10.1016\/j.ijantimicag.2023.106763_bib0002","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1016\/j.jmii.2021.04.007","article-title":"Risk of non-typhoidal Salmonella vascular infections is increased with degree of atherosclerosis and inflammation: A multicenter study in southern Taiwan","volume":"55","author":"Chen","year":"2022","journal-title":"J Microbiol Immunol Infect"},{"key":"10.1016\/j.ijantimicag.2023.106763_bib0003","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijantimicag.2022.106591","article-title":"Epidemiology and age-related mortality in critically ill patients with intra-abdominal infection or sepsis: an international cohort study","volume":"60","author":"Arvaniti","year":"2022","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.ijantimicag.2023.106763_bib0004","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijantimicag.2022.106614","article-title":"Comparative efficacy and safety of systemic antifungal agents for candidemia: a systematic review with network meta-analysis and multicriteria acceptability analyses","volume":"60","author":"Domingos","year":"2022","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.ijantimicag.2023.106763_bib0005","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijantimicag.2022.106604","article-title":"Effectiveness of antimicrobial stewardship programmes based on rapid antibiotic susceptibility testing of haematological patients having high-risk factors for bacteraemia-related mortality: a post-hoc analysis of a randomised controlled trial","volume":"60","author":"Kim","year":"2022","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.ijantimicag.2023.106763_bib0006","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/j.jmii.2021.03.017","article-title":"Antifibrotic and anthelminthic effect of casticin on Schistosoma mansoni-infected BALB\/c mice","volume":"55","author":"Lam","year":"2022","journal-title":"J Microbiol Immunol Infect"},{"key":"10.1016\/j.ijantimicag.2023.106763_bib0007","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.jmii.2020.12.004","article-title":"An outbreak of Ralstonia pickettii bloodstream infection among pediatric leukemia patients","volume":"55","author":"Bedir Demirdag","year":"2022","journal-title":"J Microbiol Immunol Infect"},{"key":"10.1016\/j.ijantimicag.2023.106763_bib0008","doi-asserted-by":"crossref","DOI":"10.3389\/fcimb.2022.823684","article-title":"Global threat of carbapenem-resistant Gram-negative bacteria","volume":"12","author":"Jean","year":"2022","journal-title":"Front Cell Infect Microbiol"},{"key":"10.1016\/j.ijantimicag.2023.106763_bib0009","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1038\/s41579-018-0147-4","article-title":"Methicillin-resistant Staphylococcus aureus: an overview of basic and clinical research","volume":"17","author":"Turner","year":"2019","journal-title":"Nat Rev Microbiol"},{"key":"10.1016\/j.ijantimicag.2023.106763_bib0010","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1080\/22221751.2019.1595161","article-title":"Decreasing methicillin-resistant Staphylococcus aureus (MRSA) infections is attributable to the disappearance of predominant MRSA ST239 clones, Shanghai, 2008\u20132017","volume":"8","author":"Dai","year":"2019","journal-title":"Emerg Microbes Infect"},{"key":"10.1016\/j.ijantimicag.2023.106763_bib0011","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1128\/CMR.13.4.686","article-title":"Vancomycin-resistant enterococci","volume":"13","author":"Cetinkaya","year":"2000","journal-title":"Clin Microbiol Rev"},{"key":"10.1016\/j.ijantimicag.2023.106763_bib0012","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1016\/j.jmii.2019.02.002","article-title":"Real-time PCR for the rapid detection of vanA, vanB and vanM genes","volume":"53","author":"He","year":"2020","journal-title":"J Microbiol Immunol Infect"},{"key":"10.1016\/j.ijantimicag.2023.106763_bib0013","series-title":"Performance standards for antimicrobial susceptibility testing: 32nd informational supplement M100\u2013S32","year":"2022"},{"key":"10.1016\/j.ijantimicag.2023.106763_bib0014","series-title":"Breakpoint tables for interpretation of MICs and zone diameters","year":"2022"},{"key":"10.1016\/j.ijantimicag.2023.106763_bib0015","unstructured":"US Food and Drug Administration. Antibacterial susceptibility test interpretive criteria. Available at: https:\/\/www.fda.gov\/drugs\/development-resources\/antibacterial-susceptibility-test-interpretive-criteria [accessed 21 January 2023]."},{"key":"10.1016\/j.ijantimicag.2023.106763_bib0016","doi-asserted-by":"crossref","first-page":"2169","DOI":"10.1056\/NEJMoa1310480","article-title":"Once-weekly dalbavancin versus daily conventional therapy for skin infection","volume":"370","author":"Boucher","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijantimicag.2023.106763_bib0017","doi-asserted-by":"crossref","first-page":"ofac335","DOI":"10.1093\/ofid\/ofac335","article-title":"Comparison of sequential dalbavancin with standard-of-care treatment for Staphylococcus aureus bloodstream infections","volume":"9","author":"Molina","year":"2022","journal-title":"Open Forum Infect Dis"},{"key":"10.1016\/j.ijantimicag.2023.106763_bib0018","first-page":"532","article-title":"Dalbavancin for treating prosthetic joint infections caused by Gram-positive bacteria: A proposal for a low dose strategy. A retrospective cohort study","volume":"32","author":"Buz\u00f3n Mart\u00edn","year":"2019","journal-title":"Rev Esp Quimioter"},{"key":"10.1016\/j.ijantimicag.2023.106763_bib0019","doi-asserted-by":"crossref","first-page":"dlaa114","DOI":"10.1093\/jacamr\/dlaa114","article-title":"Treatment of methicillin-resistant Staphylococcus aureus (MRSA): updated guidelines from the UK","volume":"3","author":"Brown","year":"2021","journal-title":"JAC Antimicrob Resist"},{"key":"10.1016\/j.ijantimicag.2023.106763_bib0020","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.1128\/AAC.04550-14","article-title":"Extended-duration dosing and distribution of dalbavancin into bone and articular tissue","volume":"59","author":"Dunne","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2023.106763_bib0021","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/j.ijid.2019.02.013","article-title":"Multicenter clinical experience of real life dalbavancin use in gram-positive infections","volume":"81","author":"Wunsch","year":"2019","journal-title":"Int J Infect Dis"},{"key":"10.1016\/j.ijantimicag.2023.106763_bib0022","doi-asserted-by":"crossref","first-page":"ofy331","DOI":"10.1093\/ofid\/ofy331","article-title":"Dalbavancin for the treatment of osteomyelitis in adult patients: A randomized clinical trial of efficacy and safety","volume":"6","author":"Rappo","year":"2018","journal-title":"Open Forum Infect Dis"},{"key":"10.1016\/j.ijantimicag.2023.106763_bib0023","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.12659\/AJCR.905930","article-title":"Multiple weekly dalbavancin dosing for the treatment of native vertebral osteomyelitis caused by methicillin-resistant Staphylococcus aureus: A case report","volume":"18","author":"Almangour","year":"2017","journal-title":"Am J Case Rep"},{"key":"10.1016\/j.ijantimicag.2023.106763_bib0024","doi-asserted-by":"crossref","first-page":"dlab099","DOI":"10.1093\/jacamr\/dlab099","article-title":"Use of dalbavancin in infective endocarditis: a case series","volume":"3","author":"Guleri","year":"2021","journal-title":"JAC Antimicrob Resist"},{"key":"10.1016\/j.ijantimicag.2023.106763_bib0025","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1093\/cid\/ciy279","article-title":"Dalbavancin as primary and sequential treatment for Gram-positive infective endocarditis: 2-year experience at the general hospital of Vienna","volume":"67","author":"Tobudic","year":"2018","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2023.106763_bib0026","doi-asserted-by":"crossref","first-page":"4422","DOI":"10.1128\/AAC.00231-09","article-title":"Oritavancin population pharmacokinetics in healthy subjects and patients with complicated skin and skin structure infections or bacteremia","volume":"53","author":"Rubino","year":"2009","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2023.106763_bib0027","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1093\/cid\/ciu778","article-title":"Single-dose oritavancin versus 7-10 days of vancomycin in the treatment of gram-positive acute bacterial skin and skin structure infections: the SOLO II noninferiority study","volume":"60","author":"Corey","year":"2015","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2023.106763_bib0028","doi-asserted-by":"crossref","first-page":"2180","DOI":"10.1056\/NEJMoa1310422","article-title":"Single-dose oritavancin in the treatment of acute bacterial skin infections","volume":"370","author":"Corey","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijantimicag.2023.106763_bib0029","doi-asserted-by":"crossref","first-page":"S203","DOI":"10.1093\/cid\/cir923","article-title":"Oritavancin microbiologic features and activity results from the surveillance program in the United States","volume":"54","author":"Mendes","year":"2012","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2023.106763_bib0030","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1093\/jac\/dks344","article-title":"Activity of oritavancin against methicillin-resistant staphylococci, vancomycin-resistant enterococci and \u03b2-haemolytic streptococci collected from western European countries in 2011","volume":"68","author":"Morrissey","year":"2013","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2023.106763_bib0031","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1007\/s40801-020-00194-8","article-title":"Real-World Use of Oritavancin for the treatment of osteomyelitis","volume":"7","author":"Scoble","year":"2020","journal-title":"Drugs Real World Outcomes"},{"key":"10.1016\/j.ijantimicag.2023.106763_bib0032","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1007\/s40801-020-00195-7","article-title":"Treatment of acute osteomyelitis with once-weekly oritavancin: A two-year, multicenter, retrospective study","volume":"7","author":"Van Hise","year":"2020","journal-title":"Drugs Real World Outcomes"},{"key":"10.1016\/j.ijantimicag.2023.106763_bib0033","doi-asserted-by":"crossref","first-page":"ofz479","DOI":"10.1093\/ofid\/ofz479","article-title":"The CHROME study, a real-world experience of single- and multiple-dose oritavancin for treatment of Gram-positive infections","volume":"6","author":"Redell","year":"2019","journal-title":"Open Forum Infect Dis"},{"key":"10.1016\/j.ijantimicag.2023.106763_bib0034","doi-asserted-by":"crossref","first-page":"ofv156","DOI":"10.1093\/ofid\/ofv156","article-title":"Prolonged use of oritavancin for vancomycin-resistant Enterococcus faecium prosthetic valve endocarditis","volume":"2","author":"Johnson","year":"2015","journal-title":"Open Forum Infect Dis"},{"key":"10.1016\/j.ijantimicag.2023.106763_bib0035","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1128\/AAC.49.3.1127-1134.2005","article-title":"Telavancin, a multifunctional lipoglycopeptide, disrupts both cell wall synthesis and cell membrane integrity in methicillin-resistant Staphylococcus aureus","volume":"49","author":"Higgins","year":"2005","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2023.106763_bib0036","doi-asserted-by":"crossref","first-page":"2647","DOI":"10.1128\/AAC.01398-07","article-title":"In vitro activity of telavancin against resistant gram-positive bacteria","volume":"52","author":"Krause","year":"2008","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2023.106763_bib0037","doi-asserted-by":"crossref","first-page":"1683","DOI":"10.1086\/587896","article-title":"Telavancin versus vancomycin for the treatment of complicated skin and skin-structure infections caused by gram-positive organisms","volume":"46","author":"Stryjewski","year":"2008","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2023.106763_bib0038","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1093\/cid\/ciq031","article-title":"Telavancin versus vancomycin for hospital-acquired pneumonia due to gram-positive pathogens","volume":"52","author":"Rubinstein","year":"2011","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2023.106763_bib0039","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1016\/j.diagmicrobio.2017.09.004","article-title":"Telavancin for the treatment of methicillin-resistant Staphylococcus aureus bone and joint infections","volume":"89","author":"Harting","year":"2017","journal-title":"Diagn Microbiol Infect Dis"},{"key":"10.1016\/j.ijantimicag.2023.106763_bib0040","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.ijantimicag.2017.01.034","article-title":"Outpatient treatment of osteomyelitis with telavancin","volume":"50","author":"Schroeder","year":"2017","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.ijantimicag.2023.106763_bib0041","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.diagmicrobio.2019.05.011","article-title":"Real-world use of telavancin in the treatment of osteomyelitis","volume":"95","author":"Saravolatz","year":"2019","journal-title":"Diagn Microbiol Infect Dis"},{"key":"10.1016\/j.ijantimicag.2023.106763_bib0042","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1007\/s40801-020-00191-x","article-title":"Clinical experience with telavancin for the treatment of patients with bacteremia and endocarditis: Real-world results from the telavancin observational use registry (TOUR\u2122)","volume":"7","author":"Reilly","year":"2020","journal-title":"Drugs Real World Outcomes"},{"key":"10.1016\/j.ijantimicag.2023.106763_bib0043","doi-asserted-by":"crossref","first-page":"2373","DOI":"10.1128\/AAC.01266-06","article-title":"Efficacy of telavancin in the treatment of experimental endocarditis due to glycopeptide-intermediate Staphylococcus aureus","volume":"51","author":"Mir\u00f3","year":"2007","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2023.106763_bib0044","doi-asserted-by":"crossref","first-page":"2890","DOI":"10.1093\/jac\/dkw249","article-title":"Comparative efficacy of telavancin and daptomycin in experimental endocarditis due to multi-clonotype MRSA strains","volume":"71","author":"Xiong","year":"2016","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2023.106763_bib0045","doi-asserted-by":"crossref","first-page":"379","DOI":"10.3109\/00365548.2014.995696","article-title":"Telavancin for refractory methicillin-resistant Staphylococcus aureus bacteremia and infective endocarditis","volume":"47","author":"Ruggero","year":"2015","journal-title":"Infect Dis"},{"key":"10.1016\/j.ijantimicag.2023.106763_bib0046","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1093\/jac\/dkp503","article-title":"Binding of ceftaroline to penicillin-binding proteins of Staphylococcus aureus and Streptococcus pneumoniae","volume":"65","author":"Moisan","year":"2010","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2023.106763_bib0047","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1086\/655827","article-title":"Integrated analysis of CANVAS 1 and 2: phase 3, multicenter, randomized, double-blind studies to evaluate the safety and efficacy of ceftaroline versus vancomycin plus aztreonam in complicated skin and skin-structure infection","volume":"51","author":"Corey","year":"2010","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2023.106763_bib0048","doi-asserted-by":"crossref","first-page":"e02015","DOI":"10.1128\/AAC.02015-16","article-title":"Multicenter observational study of ceftaroline fosamil for methicillin-resistant Staphylococcus aureus bloodstream infections","volume":"61","author":"Zasowski","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2023.106763_bib0049","doi-asserted-by":"crossref","first-page":"1494","DOI":"10.1128\/AAC.02274-13","article-title":"Ceftaroline restores daptomycin activity against daptomycin-nonsusceptible vancomycin-resistant Enterococcus faecium","volume":"58","author":"Sakoulas","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2023.106763_bib0050","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1080\/1120009X.2017.1351729","article-title":"Ceftaroline for the treatment of osteomyelitis caused by methicillin-resistant Staphylococcus aureus: a case series","volume":"30","author":"Lalikian","year":"2018","journal-title":"J Chemother"},{"key":"10.1016\/j.ijantimicag.2023.106763_bib0051","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1186\/s12879-019-3791-z","article-title":"Use of ceftaroline fosamil in osteomyelitis: CAPTURE study experience","volume":"19","author":"Johnson","year":"2019","journal-title":"BMC Infect Dis"},{"key":"10.1016\/j.ijantimicag.2023.106763_bib0052","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.1093\/jac\/dkq193","article-title":"Efficacy of the new cephalosporin ceftaroline in the treatment of experimental methicillin-resistant Staphylococcus aureus acute osteomyelitis","volume":"65","author":"Jacqueline","year":"2010","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2023.106763_bib0053","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1016\/j.ijid.2020.11.130","article-title":"Ceftaroline activity against Staphylococcus aureus isolated from patients with infective endocarditis, worldwide (2010\u20132019)","volume":"102","author":"Sader","year":"2021","journal-title":"Int J Infect Dis"},{"key":"10.1016\/j.ijantimicag.2023.106763_bib0054","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1007\/s10156-012-0449-9","article-title":"The use of ceftaroline fosamil in methicillin-resistant Staphylococcus aureus endocarditis and deep-seated MRSA infections: a retrospective case series of 10 patients","volume":"19","author":"Lin","year":"2013","journal-title":"J Infect Chemother"},{"key":"10.1016\/j.ijantimicag.2023.106763_bib0055","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1016\/j.ijantimicag.2019.01.014","article-title":"Ceftaroline fosamil for the treatment of Gram-positive endocarditis: CAPTURE study experience","volume":"53","author":"Destache","year":"2019","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.ijantimicag.2023.106763_bib0056","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1128\/AAC.00551-07","article-title":"Results of a double-blind, randomized trial of ceftobiprole treatment of complicated skin and skin structure infections caused by gram-positive bacteria","volume":"52","author":"Noel","year":"2008","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2023.106763_bib0057","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1086\/526527","article-title":"A randomized, double-blind trial comparing ceftobiprole medocaril with vancomycin plus ceftazidime for the treatment of patients with complicated skin and skin-structure infections","volume":"46","author":"Noel","year":"2008","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2023.106763_bib0058","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1093\/cid\/ciu219","article-title":"A phase 3 randomized double-blind comparison of ceftobiprole medocaril versus ceftazidime plus linezolid for the treatment of hospital-acquired pneumonia","volume":"59","author":"Awad","year":"2014","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2023.106763_bib0059","doi-asserted-by":"crossref","first-page":"e61","DOI":"10.1093\/cid\/ciw353","article-title":"Management of adults with hospital-acquired and ventilator-associated pneumonia: 2016 clinical practice guidelines by the Infectious Diseases Society of America and the American Thoracic Society","volume":"63","author":"Kalil","year":"2016","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2023.106763_bib0060","unstructured":"Basilea Medical Ltd. Summary of Product Characteristics: Zevtera 500 mg powder for concentrate for solution for infusion. Medicines and Healthcare Products Regulatory Agency. Available at: http:\/\/www.mhra.gov.uk\/spc [accessed 24 January 2023]."},{"key":"10.1016\/j.ijantimicag.2023.106763_bib0061","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.jgar.2019.07.020","article-title":"Ceftobiprole for the treatment of infective endocarditis: A case series","volume":"20","author":"Tascini","year":"2020","journal-title":"J Glob Antimicrob Resist"},{"key":"10.1016\/j.ijantimicag.2023.106763_bib0062","doi-asserted-by":"crossref","first-page":"1476","DOI":"10.1128\/AAC.06057-11","article-title":"Synergistic activity of ceftobiprole and vancomycin in a rat model of infective endocarditis caused by methicillin-resistant and glycopeptide-intermediate Staphylococcus aureus","volume":"56","author":"Fernandez","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2023.106763_bib0063","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1093\/cid\/cix024","article-title":"Effect of daptomycin dose on the outcome of vancomycin-resistant, daptomycin-susceptible Enterococcus faecium bacteremia","volume":"64","author":"Chuang","year":"2017","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2023.106763_bib0064","doi-asserted-by":"crossref","first-page":"1632","DOI":"10.1038\/s41598-018-19986-8","article-title":"A retrospective clinical comparison of daptomycin vs daptomycin and a beta-lactam antibiotic for treating vancomycin-resistant Enterococcus faecium bloodstream infections","volume":"8","author":"Chuang","year":"2018","journal-title":"Sci Rep"},{"key":"10.1016\/j.ijantimicag.2023.106763_bib0065","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1186\/2047-783X-15-12-533","article-title":"Comparison of the pharmacokinetic properties of vancomycin, linezolid, tigecycline, and daptomycin","volume":"15","author":"Estes","year":"2010","journal-title":"Eur J Med Res"},{"key":"10.1016\/j.ijantimicag.2023.106763_bib0066","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1186\/1471-2334-12-133","article-title":"Daptomycin therapy for osteomyelitis: a retrospective study","volume":"12","author":"Gallagher","year":"2012","journal-title":"BMC Infect Dis"},{"key":"10.1016\/j.ijantimicag.2023.106763_bib0067","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1007\/s10096-015-2515-6","article-title":"Daptomycin for the treatment of osteomyelitis and orthopaedic device infections: real-world clinical experience from a European registry","volume":"35","author":"Malizos","year":"2016","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"10.1016\/j.ijantimicag.2023.106763_bib0068","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1056\/NEJMcp0910753","article-title":"Clinical practice. Vertebral osteomyelitis","volume":"362","author":"Zimmerli","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijantimicag.2023.106763_bib0069","doi-asserted-by":"crossref","first-page":"e18","DOI":"10.1093\/cid\/ciq146","article-title":"Clinical practice guidelines by the Infectious Diseases Society of America for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children","volume":"52","author":"Liu","year":"2011","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2023.106763_bib0070","doi-asserted-by":"crossref","first-page":"1650","DOI":"10.1093\/cid\/ciy749","article-title":"Pharmacodynamic analysis of daptomycin-treated enterococcal bacteremia: it is time to change the breakpoint","volume":"68","author":"Avery","year":"2019","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2023.106763_bib0071","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1128\/AAC.47.4.1318-1323.2003","article-title":"Daptomycin pharmacokinetics and safety following administration of escalating doses once daily to healthy subjects","volume":"47","author":"Dvorchik","year":"2003","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2023.106763_bib0072","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1016\/j.cmi.2020.04.027","article-title":"Daptomycin in the treatment of enterococcal bloodstream infections and endocarditis: a EUCAST position paper","volume":"26","author":"Turnidge","year":"2020","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.ijantimicag.2023.106763_bib0073","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.1128\/AAC.01307-08","article-title":"Relationship between susceptibility to daptomycin in vitro and activity in vivo in a rabbit model of aortic valve endocarditis","volume":"53","author":"Chambers","year":"2009","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2023.106763_bib0074","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1093\/jac\/dks467","article-title":"Daptomycin for the treatment of infective endocarditis: results from a European registry","volume":"68","author":"Dohmen","year":"2013","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2023.106763_bib0075","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1016\/S1473-3099(14)70737-6","article-title":"Tedizolid for 6 days versus linezolid for 10 days for acute bacterial skin and skin-structure infections (ESTABLISH-2): a randomised, double-blind, phase 3, non-inferiority trial","volume":"14","author":"Moran","year":"2014","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.ijantimicag.2023.106763_bib0076","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1001\/jama.2013.241","article-title":"Tedizolid phosphate vs linezolid for treatment of acute bacterial skin and skin structure infections: the ESTABLISH-1 randomized trial","volume":"309","author":"Prokocimer","year":"2013","journal-title":"JAMA"},{"key":"10.1016\/j.ijantimicag.2023.106763_bib0077","doi-asserted-by":"crossref","first-page":"7198","DOI":"10.1128\/AAC.03509-14","article-title":"Platelet profile in patients with acute bacterial skin and skin structure infections receiving tedizolid or linezolid: findings from the phase 3 ESTABLISH clinical trials","volume":"58","author":"Lodise","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2023.106763_bib0078","first-page":"e01453","article-title":"Thrombocytopenia with tedizolid and linezolid","volume":"62","author":"Lee","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2023.106763_bib0079","doi-asserted-by":"crossref","first-page":"31","DOI":"10.3389\/fmed.2019.00031","article-title":"Comparative Efficacies of Linezolid vs. Tedizolid in an experimental murine model of vancomycin-resistant enterococcal (VRE) bacteremia","volume":"6","author":"Abdelhady","year":"2019","journal-title":"Front Med (Lausanne)"},{"key":"10.1016\/j.ijantimicag.2023.106763_bib0080","doi-asserted-by":"crossref","first-page":"53","DOI":"10.3390\/antibiotics10010053","article-title":"Long-term use of tedizolid in osteoarticular infections: benefits among oxazolidinone drugs","volume":"10","author":"Benavent","year":"2021","journal-title":"Antibiotics (Basel)"},{"key":"10.1016\/j.ijantimicag.2023.106763_bib0081","doi-asserted-by":"crossref","first-page":"6568","DOI":"10.1128\/AAC.01248-16","article-title":"Activity of Tedizolid in methicillin-resistant Staphylococcus aureus experimental foreign body-associated osteomyelitis","volume":"60","author":"Park","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2023.106763_bib0082","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1093\/jac\/dky473","article-title":"Evaluation of the ability of linezolid and tedizolid to eradicate intraosteoblastic and biofilm-embedded Staphylococcus aureus in the bone and joint infection setting","volume":"74","author":"Abad","year":"2019","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2023.106763_bib0083","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1016\/j.amjsurg.2009.08.045","article-title":"Efficacy and safety of linezolid versus vancomycin for the treatment of complicated skin and soft-tissue infections proven to be caused by methicillin-resistant Staphylococcus aureus","volume":"199","author":"Itani","year":"2010","journal-title":"Am J Surg"},{"key":"10.1016\/j.ijantimicag.2023.106763_bib0084","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1093\/cid\/cir895","article-title":"Linezolid in methicillin-resistant Staphylococcus aureus nosocomial pneumonia: a randomized, controlled study","volume":"54","author":"Wunderink","year":"2012","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2023.106763_bib0085","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1007\/s15010-004-3029-9","article-title":"Linezolid in the treatment of osteomyelitis: results of compassionate use experience","volume":"32","author":"Rayner","year":"2004","journal-title":"Infection"},{"key":"10.1016\/j.ijantimicag.2023.106763_bib0086","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1016\/j.clinthera.2006.08.001","article-title":"Effectiveness and tolerability of prolonged linezolid treatment for chronic osteomyelitis: a retrospective study","volume":"28","author":"Senneville","year":"2006","journal-title":"Clin Ther"},{"key":"10.1016\/j.ijantimicag.2023.106763_bib0087","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1111\/j.1469-0691.2006.01585.x","article-title":"Linezolid therapy for infective endocarditis","volume":"13","author":"Mu\u00f1oz","year":"2007","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.ijantimicag.2023.106763_bib0088","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1186\/s13104-017-2907-z","article-title":"A complicated prosthetic valve endocarditis due to methicillin resistant Staphylococci treated with linezolid and ciprofloxacin: a case report","volume":"10","author":"Amiyangoda","year":"2017","journal-title":"BMC Res Notes"},{"key":"10.1016\/j.ijantimicag.2023.106763_bib0089","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1016\/j.ijantimicag.2017.06.021","article-title":"Role of vancomycin in the treatment of bacteraemia and meningitis caused by Elizabethkingia meningoseptica","volume":"50","author":"Jean","year":"2017","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.ijantimicag.2023.106763_bib0090","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1161\/CIR.0000000000000296","article-title":"Infective endocarditis in adults: diagnosis, antimicrobial therapy, and management of complications: a scientific statement for healthcare professionals from the American Heart Association","volume":"132","author":"Baddour","year":"2015","journal-title":"Circulation"},{"key":"10.1016\/j.ijantimicag.2023.106763_bib0091","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1007\/s40265-019-01112-1","article-title":"New drugs for multidrug-resistant gram-negative organisms: time for stewardship","volume":"79","author":"Jean","year":"2019","journal-title":"Drugs"},{"key":"10.1016\/j.ijantimicag.2023.106763_bib0092","doi-asserted-by":"crossref","first-page":"407","DOI":"10.2217\/fmb.14.135","article-title":"Carbapenemase-producing Gram-negative bacteria: current epidemics, antimicrobial susceptibility and treatment options","volume":"10","author":"Jean","year":"2015","journal-title":"Future Microbiol"},{"key":"10.1016\/j.ijantimicag.2023.106763_bib0093","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1016\/j.jmii.2021.07.015","article-title":"Multicenter surveillance of antimicrobial susceptibilities and resistance mechanisms among Enterobacterales species and non-fermenting Gram-negative bacteria from different infection sources in Taiwan from 2016 to 2018","volume":"55","author":"Jean","year":"2022","journal-title":"J Microbiol Immunol Infect"},{"key":"10.1016\/j.ijantimicag.2023.106763_bib0094","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1016\/j.jmii.2020.03.017","article-title":"The first imported case of extensively drug-resistant Salmonella enterica serotype Typhi infection in Taiwan and the antimicrobial therapy","volume":"54","author":"Liu","year":"2021","journal-title":"J Microbiol Immunol Infect"},{"key":"10.1016\/j.ijantimicag.2023.106763_bib0095","unstructured":"Taiwan Nosocomial Infection Surveillance [TNIS] 2017. The Centers for Disease Control and Prevention, Taiwan. Available at: https:\/\/www.cdc.gov.tw\/professional\/downloadfile.aspx?fid=42C15EB49614A4B6 [accessed 26 June 2022]."},{"key":"10.1016\/j.ijantimicag.2023.106763_bib0096","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0186195","article-title":"Carbapenem-resistant Enterobacteriaceae colonization (CRE) and subsequent risk of infection and 90-day mortality in critically ill patients, an observational study","volume":"12","author":"McConville","year":"2017","journal-title":"PLoS One"},{"key":"10.1016\/j.ijantimicag.2023.106763_bib0097","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1111\/j.1469-0691.2012.03888.x","article-title":"Asymptomatic rectal carriage of blaKPC producing carbapenem-resistant Enterobacteriaceae: who is prone to become clinically infected?","volume":"19","author":"Schechner","year":"2013","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.ijantimicag.2023.106763_bib0098","doi-asserted-by":"crossref","first-page":"2319","DOI":"10.1007\/s10096-017-3063-z","article-title":"Activity of the novel siderophore cephalosporin cefiderocol against multidrug-resistant Gram-negative pathogens","volume":"36","author":"Dobias","year":"2017","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"10.1016\/j.ijantimicag.2023.106763_bib0099","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1080\/14787210.2016.1204911","article-title":"The antibiotic pipeline for multi-drug resistant gram negative bacteria: what can we expect?","volume":"14","author":"Falagas","year":"2016","journal-title":"Expert Rev Anti Infect Ther"},{"key":"10.1016\/j.ijantimicag.2023.106763_bib0100","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1093\/jac\/dky425","volume":"74","author":"Hsueh","year":"2019","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2023.106763_bib0101","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1002\/phar.2334","article-title":"Compassionate Use of Cefiderocol in the treatment of an intraabdominal infection due to multidrug-resistant Pseudomonas aeruginosa: A case report","volume":"39","author":"Stevens","year":"2019","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.ijantimicag.2023.106763_bib0102","doi-asserted-by":"crossref","first-page":"dlab188","DOI":"10.1093\/jacamr\/dlab188","article-title":"Real-life experience with compassionate use of cefiderocol for difficult-to-treat resistant Pseudomonas aeruginosa (DTR-P) infections","volume":"3","author":"Meschiari","year":"2021","journal-title":"JAC Antimicrob Resist"},{"key":"10.1016\/j.ijantimicag.2023.106763_bib0103","doi-asserted-by":"crossref","first-page":"e01872","DOI":"10.1128\/AAC.01872-19","article-title":"Long-term compassionate use of cefiderocol to treat chronic osteomyelitis caused by extensively drug-resistant Pseudomonas aeruginosa and extended-spectrum-\u03b2-lactamase-producing Klebsiella pneumoniae in a pediatric patient","volume":"64","author":"Alamarat","year":"2020","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2023.106763_bib0104","doi-asserted-by":"crossref","first-page":"i18","DOI":"10.1093\/jacamr\/dlab054","article-title":"Education: A compassionate use of cefiderocol to treat osteomyelitis caused by an XDR Pseudomonas aeruginosa","volume":"3","author":"Chavda","year":"2021","journal-title":"JAC Antimicrob Resist"},{"key":"10.1016\/j.ijantimicag.2023.106763_bib0105","doi-asserted-by":"crossref","first-page":"ofaa150","DOI":"10.1093\/ofid\/ofaa150","article-title":"Case report: Successful rescue therapy of extensively drug-resistant Acinetobacter baumannii osteomyelitis with cefiderocol","volume":"7","author":"Dagher","year":"2020","journal-title":"Open Forum Infect Dis"},{"key":"10.1016\/j.ijantimicag.2023.106763_bib0106","doi-asserted-by":"crossref","first-page":"ofaa185","DOI":"10.1093\/ofid\/ofaa185","article-title":"Cefiderocol for extensively drug-resistant Gram-negative bacterial infections: Real-world experience from a case series and review of the literature","volume":"7","author":"Zingg","year":"2020","journal-title":"Open Forum Infect Dis"},{"key":"10.1016\/j.ijantimicag.2023.106763_bib0107","doi-asserted-by":"crossref","first-page":"1932","DOI":"10.1093\/cid\/ciy963","article-title":"Compassionate use of cefiderocol as adjunctive treatment of native aortic valve endocarditis due to extremely drug-resistant Pseudomonas aeruginosa","volume":"68","author":"Edgeworth","year":"2019","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2023.106763_bib0108","doi-asserted-by":"crossref","first-page":"74","DOI":"10.3389\/fmed.2019.00074","article-title":"Treatment of infections due to MDR Gram-negative bacteria","volume":"6","author":"Bassetti","year":"2019","journal-title":"Front Med (Lausanne)"},{"key":"10.1016\/j.ijantimicag.2023.106763_bib0109","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1016\/j.jmii.2021.09.009","article-title":"Clinical characteristics and outcomes of non-cystic fibrosis patients with Burkholderia cepacia complex bacteremia at a medical center in Taiwan","volume":"55","author":"Chang","year":"2022","journal-title":"J Microbiol Immunol Infect"},{"key":"10.1016\/j.ijantimicag.2023.106763_bib0110","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.jmii.2020.12.012","article-title":"Emergence of concurrent levofloxacin- and trimethoprim\/sulfamethoxazole-resistant Stenotrophomonas maltophilia: Risk factors and antimicrobial sensitivity pattern analysis from a single medical center in Taiwan","volume":"55","author":"Wu","year":"2022","journal-title":"J Microbiol Immunol Infect"},{"key":"10.1016\/j.ijantimicag.2023.106763_bib0111","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijantimicag.2021.106487","article-title":"Intrapulmonary pharmacokinetics of high doses of tigecycline in patients with ventilator-associated pneumonia","volume":"59","author":"Dimopoulos","year":"2022","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.ijantimicag.2023.106763_bib0112","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1186\/cc13942","article-title":"High dose of tigecycline for extremely resistant Gram-negative pneumonia: yes, we can","volume":"18","author":"Garnacho-Montero","year":"2014","journal-title":"Crit Care"},{"key":"10.1016\/j.ijantimicag.2023.106763_bib0113","doi-asserted-by":"crossref","DOI":"10.1155\/2016\/8395268","article-title":"Tigecycline therapy for nosocomial pneumonia due to carbapenem-resistant Gram-negative bacteria in critically ill patients who received inappropriate initial antibiotic treatment: A retrospective case study","volume":"2016","author":"Wu","year":"2016","journal-title":"Biomed Res Int"},{"key":"10.1016\/j.ijantimicag.2023.106763_bib0114","doi-asserted-by":"crossref","first-page":"1756","DOI":"10.1128\/AAC.01232-12","article-title":"Randomized phase 2 trial to evaluate the clinical efficacy of two high-dosage tigecycline regimens versus imipenem-cilastatin for treatment of hospital-acquired pneumonia","volume":"57","author":"Ramirez","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2023.106763_bib0115","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1093\/jac\/dki109","article-title":"Comparative evaluation of tigecycline and vancomycin, with and without rifampicin, in the treatment of methicillin-resistant Staphylococcus aureus experimental osteomyelitis in a rabbit model","volume":"55","author":"Yin","year":"2005","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2023.106763_bib0116","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/j.diagmicrobio.2013.07.014","article-title":"Tigecycline in the management of osteomyelitis: a case series from the bone and joint infection (BAJIO) database","volume":"77","author":"Griffin","year":"2013","journal-title":"Diagn Microbiol Infect Dis"},{"key":"10.1016\/j.ijantimicag.2023.106763_bib0117","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1186\/s13256-017-1357-5","article-title":"Prolonged and high dosage of tigecycline - successful treatment of spondylodiscitis caused by multidrug-resistant Acinetobacter baumannii: a case report","volume":"11","author":"Tsachouridou","year":"2017","journal-title":"J Med Case Rep"},{"key":"10.1016\/j.ijantimicag.2023.106763_bib0118","doi-asserted-by":"crossref","first-page":"2108","DOI":"10.1345\/aph.1M324","article-title":"Multidrug-resistant Enterococcus faecium endocarditis treated with combination tigecycline and high-dose daptomycin","volume":"43","author":"Schutt","year":"2009","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.ijantimicag.2023.106763_bib0119","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1002\/jhm.236","article-title":"Linezolid- and vancomycin-resistant Enterococcus faecium endocarditis: successful treatment with tigecycline and daptomycin","volume":"2","author":"Jenkins","year":"2007","journal-title":"J Hosp Med"},{"key":"10.1016\/j.ijantimicag.2023.106763_bib0120","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1097\/QCO.0000000000000438","article-title":"New antibiotics for ventilator-associated pneumonia","volume":"31","author":"Bassetti","year":"2018","journal-title":"Curr Opin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2023.106763_bib0121","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1016\/j.jgar.2021.10.020","article-title":"A retrospective multicenter evaluation of eravacycline utilization in community and academic Hospitals","volume":"29","author":"Hobbs","year":"2022","journal-title":"J Glob Antimicrob Resist"},{"key":"10.1016\/j.ijantimicag.2023.106763_bib0122","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1007\/s40121-020-00351-0","article-title":"A real-world assessment of clinical outcomes and safety of eravacycline: A novel fluorocycline","volume":"9","author":"Hise","year":"2020","journal-title":"Infect Dis Ther"},{"key":"10.1016\/j.ijantimicag.2023.106763_bib0123","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/j.ijid.2021.10.022","article-title":"Antimicrobial activities of ceftazidime\/avibactam, ceftolozane\/tazobactam, imipenem\/relebactam, meropenem\/vaborbactam, and comparators against Pseudomonas aeruginosa from patients with skin and soft tissue infections","volume":"113","author":"Sader","year":"2021","journal-title":"Int J Infect Dis"},{"key":"10.1016\/j.ijantimicag.2023.106763_bib0124","first-page":"128","article-title":"Ceftazidime\/avibactam for refractory bacteremia, vertebral diskitis\/osteomyelitis with pre-vertebral abscess and bilateral psoas pyomyositis secondary to Klebsiella Pneumoniae carbapenemase-producing bacteria (KPC)","volume":"37","author":"Le\u00f3n-Borr\u00e1s","year":"2018","journal-title":"P R Health Sci J"},{"key":"10.1016\/j.ijantimicag.2023.106763_bib0125","doi-asserted-by":"crossref","first-page":"3109","DOI":"10.2147\/IDR.S320056","article-title":"Carbapenem-resistant Klebsiella pneumoniae osteomyelitis treated with ceftazidime-avibactam in an infant: A case report","volume":"14","author":"Ji","year":"2021","journal-title":"Infect Drug Resist"},{"key":"10.1016\/j.ijantimicag.2023.106763_bib0126","doi-asserted-by":"crossref","first-page":"e12837","DOI":"10.1111\/tid.12837","article-title":"Carbapenem-resistant Klebsiella pneumoniae vertebral osteomyelitis in a renal transplant recipient treated with ceftazidime-avibactam","volume":"20","author":"Cani","year":"2018","journal-title":"Transpl Infect Dis"},{"key":"10.1016\/j.ijantimicag.2023.106763_bib0127","article-title":"Prosthetic joint infection from carbapenemase-resistant Klebsiella pneumoniae successfully treated with ceftazidime-avibactam","volume":"2018","author":"Schimmenti","year":"2018","journal-title":"Case Rep Infect Dis"},{"key":"10.1016\/j.ijantimicag.2023.106763_bib0128","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1093\/cid\/cix014","article-title":"Multicenter evaluation of ceftolozane\/tazobactam for serious infections caused by carbapenem-resistant Pseudomonas aeruginosa","volume":"65","author":"Munita","year":"2017","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2023.106763_bib0129","doi-asserted-by":"crossref","first-page":"1983","DOI":"10.2147\/IDR.S175679","article-title":"In vitro activity of ceftazidime-avibactam, ceftolozane-tazobactam, and other comparable agents against clinically important Gram-negative bacilli: results from the 2017 Surveillance of Multicenter Antimicrobial Resistance in Taiwan (SMART)","volume":"11","author":"Jean","year":"2018","journal-title":"Infect Drug Resist"},{"key":"10.1016\/j.ijantimicag.2023.106763_bib0130","doi-asserted-by":"crossref","first-page":"5350","DOI":"10.1128\/AAC.00049-14","article-title":"Multicenter, double-blind, randomized, phase II trial to assess the safety and efficacy of ceftolozane-tazobactam plus metronidazole compared with meropenem in adult patients with complicated intra-abdominal infections","volume":"58","author":"Lucasti","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2023.106763_bib0131","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1016\/S1473-3099(19)30403-7","article-title":"Ceftolozane-tazobactam versus meropenem for treatment of nosocomial pneumonia (ASPECT-NP): a randomised, controlled, double-blind, phase 3, non-inferiority trial","volume":"19","author":"Kollef","year":"2019","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.ijantimicag.2023.106763_bib0132","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1093\/cid\/ciz816","article-title":"Ceftolozane\/tazobactam vs polymyxin or aminoglycoside-based regimens for the treatment of drug-resistant Pseudomonas aeruginosa","volume":"71","author":"Pogue","year":"2020","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2023.106763_bib0133","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.3390\/jcm10051068","article-title":"An update on eight \"new\" antibiotics against multidrug-resistant Gram-negative bacteria","volume":"10","author":"Yusuf","year":"2021","journal-title":"J Clin Med"},{"key":"10.1016\/j.ijantimicag.2023.106763_bib0134","doi-asserted-by":"crossref","first-page":"ofy280","DOI":"10.1093\/ofid\/ofy280","article-title":"Ceftolozane-tazobactam for the treatment of multidrug-resistant Pseudomonas aeruginosa infections: a multicenter study","volume":"5","author":"Gallagher","year":"2018","journal-title":"Open Forum Infect Dis"},{"key":"10.1016\/j.ijantimicag.2023.106763_bib0135","article-title":"Ceftolozane-tazobactam for the treatment of osteomyelitis caused by multidrug-resistant pathogens: a case series","volume":"11","author":"Tan","year":"2019","journal-title":"Ther Adv Drug Saf"},{"key":"10.1016\/j.ijantimicag.2023.106763_bib0136","doi-asserted-by":"crossref","DOI":"10.1177\/1178633720905977","article-title":"Experience with ceftolozane-tazobactam for the treatment of serious Pseudomonas aeruginosa infections in Saudi tertiary care center","volume":"13","author":"Bosaeed","year":"2020","journal-title":"Infect Dis (Auckl)"},{"key":"10.1016\/j.ijantimicag.2023.106763_bib0137","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijantimicag.2020.106158","article-title":"Use of continuous infusion ceftolozane\/tazobactam for resistant Gram-negative bacterial infections: a retrospective analysis and brief review of the literature","volume":"56","author":"Sheffield","year":"2020","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.ijantimicag.2023.106763_bib0138","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijantimicag.2020.105925","article-title":"In vitro efficacy of imipenem-relebactam and cefepime-AAI101 against a global collection of ESBL-positive and carbapenemase-producing Enterobacteriaceae","volume":"56","author":"Tselepis","year":"2020","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.ijantimicag.2023.106763_bib0139","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.jmii.2021.02.001","article-title":"Activities of imipenem-relebactam combination against carbapenem-nonsusceptible Enterobacteriaceae in Taiwan","volume":"55","author":"Yang","year":"2022","journal-title":"J Microbiol Immunol Infect"},{"key":"10.1016\/j.ijantimicag.2023.106763_bib0140","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijantimicag.2022.106521","volume":"59","author":"Jean","year":"2022","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.ijantimicag.2023.106763_bib0141","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1007\/s40121-018-0214-1","article-title":"Effect and safety of meropenem-vaborbactam versus best-available therapy in patients with carbapenem-resistant Enterobacteriaceae infections: The TANGO II randomized clinical trial","volume":"7","author":"Wunderink","year":"2018","journal-title":"Infect Dis Ther"},{"key":"10.1016\/j.ijantimicag.2023.106763_bib0142","doi-asserted-by":"crossref","first-page":"ofaa051","DOI":"10.1093\/ofid\/ofaa051","article-title":"Real-world multicenter analysis of clinical outcomes and safety of meropenem-vaborbactam in patients treated for serious Gram-negative bacterial infections","volume":"7","author":"Alosaimy","year":"2020","journal-title":"Open Forum Infect Dis"},{"key":"10.1016\/j.ijantimicag.2023.106763_bib0143","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1093\/cid\/ciz1131","article-title":"Early experience with meropenem-vaborbactam for treatment of carbapenem-resistant Enterobacteriaceae infections","volume":"71","author":"Shields","year":"2020","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2023.106763_bib0144","doi-asserted-by":"crossref","first-page":"dlac022","DOI":"10.1093\/jacamr\/dlac022","article-title":"Compassionate use of meropenem\/vaborbactam for infections caused by KPC-producing Klebsiella pneumoniae: a multicentre study","volume":"4","author":"Tumbarello","year":"2022","journal-title":"JAC Antimicrob Resist"},{"key":"10.1016\/j.ijantimicag.2023.106763_bib0145","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1080\/14787210.2022.2021876","volume":"20","author":"Jean","year":"2022","journal-title":"Expert Rev Anti Infect Ther"},{"key":"10.1016\/j.ijantimicag.2023.106763_bib0146","doi-asserted-by":"crossref","first-page":"e00105","DOI":"10.1128\/AAC.00105-19","article-title":"Beyond piperacillin-tazobactam: cefepime and AAI101 as a potent \u03b2-lactam-\u03b2-lactamase inhibitor combination","volume":"63","author":"Papp-Wallace","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2023.106763_bib0147","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1093\/jac\/dkw593","article-title":"In vitro activity of cefepime\/zidebactam (WCK 5222) against Gram-negative bacteria","volume":"72","author":"Livermore","year":"2017","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2023.106763_bib0148","first-page":"149","article-title":"Efficacy of human-simulated bronchopulmonary exposures of cefepime, zidebactam and the combination (WCK 5222) against MDR Pseudomonas aeruginosa in a neutropenic murine pneumonia model","volume":"75","author":"Kidd","year":"2020","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2023.106763_bib0149","first-page":"e00297","article-title":"Activity of aztreonam in combination with avibactam, clavulanate, relebactam, and vaborbactam against multidrug-resistant Stenotrophomonas maltophilia","volume":"64","author":"Biagi","year":"2020","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2023.106763_bib0150","doi-asserted-by":"crossref","DOI":"10.3389\/fmicb.2021.709974","article-title":"Durlobactam, a new diazabicyclooctane \u03b2-lactamase inhibitor for the treatment of Acinetobacter infections in combination with sulbactam","volume":"12","author":"Shapiro","year":"2021","journal-title":"Front Microbiol"},{"key":"10.1016\/j.ijantimicag.2023.106763_bib0151","doi-asserted-by":"crossref","first-page":"e01506","DOI":"10.1128\/AAC.01506-19","article-title":"Pharmacokinetics and tolerability of intravenous sulbactam-durlobactam with imipenem-cilastatin in hospitalized adults with complicated urinary tract infections, including acute pyelonephritis","volume":"64","author":"Sagan","year":"2020","journal-title":"Antimicrob Agents Chemother"}],"container-title":["International Journal of Antimicrobial Agents"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924857923000511?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924857923000511?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T17:44:56Z","timestamp":1760377496000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0924857923000511"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5]]},"references-count":151,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2023,5]]}},"alternative-id":["S0924857923000511"],"URL":"https:\/\/doi.org\/10.1016\/j.ijantimicag.2023.106763","relation":{},"ISSN":["0924-8579"],"issn-type":[{"value":"0924-8579","type":"print"}],"subject":[],"published":{"date-parts":[[2023,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Off-label use versus formal recommendations of conventional and novel antibiotics for the treatment of infections caused by multidrug-resistant bacteria","name":"articletitle","label":"Article Title"},{"value":"International Journal of Antimicrobial Agents","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijantimicag.2023.106763","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Ltd and International Society of Antimicrobial Chemotherapy. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"106763"}}